Member Info for BOJO2020

it would be a £1 or more.

But wait we have three clinical trials... Ok, certainly not comparing eggs with eggs, but three eggs for 1/8th of an Avacta egg!

Certainly seems cheap

I think the point is Gracie that nobody should be telling one another or trying to influence buying or selling. One should certainly not be suggesting that they have a better opinion than another. The truth is that this is going to be hard for Angle to commercialise. Despite this fact, I personally trust Angle in so far as what they have achieved. This is way beyond the average med tech or general investment but we should never relax. We must be vigilant as it is our own money at risk. I will review this as and when I see necessary. Nobody can be totally trusted with my money!

NB we know that Angle have achieved a great deal in terms of research. The big question now is, can they commercialise it?

Fevertreeman,

Whilst you have the facade of knowing what you are talking about (too the uninitiated) it is clear to me what your objectives are.

1. Too scare and unsettle follow investors.
2. To disrupt peoples views.

The reasons for your objectives are irrelevant as are your posts IMO.

The veneer of your arguments are thin but they are populist. Anybody that believes what you are saying deserves all they get IMO. On the one hand we have your good self that alludes to being some big shot business person and on the other we have Newland and co whom, might I remind everyone are official company officers and that can and should be scrutinized. Not so any poster that wishes to express an opinion on a public bulletin board.

I would also remind everybody that we have one approval for MBC with the FDA. A multi billion $ company that does not make in 12 weeks... Not even a multi million $ company. Anybody expecting that by now is delusional.

Anybody posting factual and informative posts I would love to hear from. Fevertree, I will avoid.

Yes Donkey,

My thoughts exactly on a .58 exchange. So sold at 3.35 and bought back this am.

Just to add, both lung studies are smaller studies so they would warrant a larger study (somewhere in the region if 200 subjects based on ovarian) to attempt fda approval or clinical lab accreditation

Flatlander

Angle appears to work something like this. Small study warrants a larger study. These larger studies warrant FDA or clinical lab accreditation.

So we have MBC fda approved.

64? Small studies. These have warranted larger studies of which we have two in progress.

These are Ovarian Study and Prostate. Ovarian results are due imminently. Prostate in around 8 months or so.

Need to drill it first but….

It always surprises me that nobody mentions time as a major factor in investing. Because although market cap, share price, Investment case, scientific fact etc are important factors. Only time governs them all. Is it little wonder then that the most of us are sitting on losses.

a larger study is required in NSCLC...

Add that to ovarian and prostate studies. Will we announce a collaboration in NSCLC anytime soon. As the RNS states, there is a need with 55% of patients being diagnosed at stage VI meaning a survival rate of just 7%.

This has to be the way forward. Get these studies done and CLIA route. One of many things that AN & IG can discuss in Chicago

So the view is Parsortix is a complimentary diagnostic not a competing one? To suggest that is competing or superior would suggest a profound knowledge of the entire space. I for one do not have that knowledge!

Thanks Bermuda,

Do you have any thoughts on very early tumor cells which I believe might be counted as a zero stage cancer. Now that would be amazing Parsortix or Galleri etc could somehow capture those. Maybe a question for Andrew @ investor relations.

Good point Chazzy. I am no expert but it appears the latest thing in liquid biopsy is the DNA which is considered more stable than RNA? Clearly Parsortix offers RNA & protein too (the whole picture) but it’s just a case of presenting a body of evidence to change the narrative and current thinking. Research papers alone won’t do this IMO. Accreditation, approvals and study/clinical trials/data will push Parsortix to the top of the subject pile.

Thoughts anyone?

Thanks Bermudashorts,
That's a hearty helping of Angle and Parsortix. Great to see. This underlines AN's assertion that many companies occupy the same space. Surely working together has to be the way forward, and lets not forget, Parsortix is an enabler...

He is in Chicago. And no I don’t mean the musical

Or more likely Frank Baum has been advising Hicory, dickory, doc. Or was it mother goose…

Thanks Ivy.

Yes that sounds right. If we can execute the plan then it would be a wow.

ATB

Re we have funding. I hope we don’t burn all our cash chasing Covid19. There comes a point where we need to sell it or move on.

A few are waiting to see the conifer holding too

I am still here. Good to hear from you Nolupus.

I spend quite a bit of time on Angle tele group. Also GGP avoiding most platforms! LSE for Scancell

Many Thanks

Brilliant answer. You make it all sound so simple! Of course Angle are working exceptionally hard on these studies.

So if we say hypothetically that we have an excellent test. We then apply for CLIA which is adjudicated by FDA? The LDT by CMS?

I guess what I am asking is: what are the obstacle to be negotiated following an excellent or very good ovarian study result.